Table of Content


List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Tourette Syndrome - Overview
Tourette Syndrome - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Pipeline by Universities/Institutes
Products under Development by Companies
Products under Development by Universities/Institutes
Tourette Syndrome - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Tourette Syndrome - Companies Involved in Therapeutics Development
Adeptio Pharmaceuticals Ltd
Asari Pharma AB
Emalex Biosciences Inc
Evero Health Ltd
Noema Pharma AG
Octapharma AG
SOM Biotech SL
Teva Pharmaceutical Industries Ltd
Tourette Syndrome - Drug Profiles
alpha-dihydrotetrabezine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
bevantolol - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
deutetrabezine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
drobinol + palmidrol - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ecopipam hydrochloride - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
immune globulin (human) - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
NOE-105 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
sepranolone - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule to Antagonize DRD2 for CNS Disorders and Hormol Disorders - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Tourette Syndrome - Dormant Projects
Tourette Syndrome - Discontinued Products
Tourette Syndrome - Product Development Milestones
Featured News & Press Releases
Feb 11, 2021: New preclinical study confirms that Sepranolone suppresses tics in Tourette Syndrome
Sep 01, 2020: Emalex Biosciences Phase 2b Tourette Syndrome clinical trial reaches enrollment milestone
Mar 24, 2020: Asari Pharma to release historic Phase IIb PMDD data on schedule
Feb 20, 2020: Teva’s deutetrabezine fails in paediatric Tourette syndrome trials
Aug 28, 2019: Emalex Biosciences receives FDA Fast Track Desigtion for Ecopipam for the treatment of patients with Tourette Syndrome
Aug 14, 2019: Emalex Biosciences announces first patient enrolled in phase 2b clinical study to evaluate the efficacy and safety of Ecopipam Tablets for the treatment of Pediatric Patients with Tourette Syndrome
Aug 06, 2019: Emalex Biosciences appoints Dr. Atul R. Mahableshwarkar as Senior Vice President of Drug Development
Jun 11, 2018: Therapix Biosciences Sponsors the 2018 Annual Meeting of the European Society for the Study of Tourette Syndrome
Apr 09, 2018: Therapix Biosciences Announces Topline Results of Phase IIa Study at Yale University for Tourette Syndrome Program
Feb 28, 2018: Nuvelution Pharma Announces Commencement of Patient Enrollment in Phase II/III Clinical Study of AUSTEDO? (deutetrabezine) for the Treatment of Tourette Syndrome in Pediatric Patients
Feb 07, 2018: Therapix Biosciences Completes Pre-IND Communication With FDA on THX-110 for Tourette Syndrome: Clinical Development to Proceed as Projected
Dec 04, 2017: Therapix Biosciences Announces Completion of Enrollment of Phase IIa Study at Yale University for Tourette Syndrome Program
Oct 11, 2017: Nippon Chemiphar and SOM Biotech to Cooperate on New, Orphan Disease Indications for Bevantolol (Calvan)
May 08, 2017: Therapix Biosciences and the Hannover Medical School Enter into an Investigator-initiated Clinical Trial Agreement to Assess the Effect of TXH-TS01 in Patients with Tourette Syndrome
Jan 17, 2017: Psyadon Announces Positive Results from Phase 2b Clinical Study of Ecopipam for the Treatment of Tourette’s Syndrome in Children
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer



List of Figures


Number of Products under Development for Tourette Syndrome, 2021
Number of Products under Development by Companies, 2021
Number of Products by Targets, 2021
Number of Products by Stage and Targets, 2021
Number of Products by Mechanism of Actions, 2021
Number of Products by Stage and Top 10 Mechanism of Actions, 2021
Number of Products by Routes of Administration, 2021
Number of Products by Stage and Routes of Administration, 2021
Number of Products by Molecule Types, 2021
Number of Products by Stage and Molecule Types, 2021


List of Tables


Number of Products under Development for Tourette Syndrome, 2021
Number of Products under Development by Companies, 2021
Number of Products under Development by Universities/Institutes, 2021
Products under Development by Companies, 2021
Products under Development by Universities/Institutes, 2021
Number of Products by Stage and Target, 2021
Number of Products by Stage and Mechanism of Action, 2021
Number of Products by Stage and Route of Administration, 2021
Number of Products by Stage and Molecule Type, 2021
Tourette Syndrome - Pipeline by Adeptio Pharmaceuticals Ltd, 2021
Tourette Syndrome - Pipeline by Asarina Pharma AB, 2021
Tourette Syndrome - Pipeline by Emalex Biosciences Inc, 2021
Tourette Syndrome - Pipeline by Evero Health Ltd, 2021
Tourette Syndrome - Pipeline by Noema Pharma AG, 2021
Tourette Syndrome - Pipeline by Octapharma AG, 2021
Tourette Syndrome - Pipeline by SOM Biotech SL, 2021
Tourette Syndrome - Pipeline by Teva Pharmaceutical Industries Ltd, 2021
Tourette Syndrome - Dormant Projects, 2021
Tourette Syndrome - Discontinued Products, 2021